Nuvation Bio reports updated Phase 2 safusidenib data, expands IDH1-mutant glioma studies
NUVB•Clinical program expansion
Clinical program expansion outlined, including a new ex-U.S. Phase 3 study G307.
- New U.S. Phase 2 study G209 targets patients progressing on vorasidenib.
Updated Phase 2 safusidenib data in grade 2 IDH1-mutant glioma
Nuvation Bio posted an announcement on updated Phase 2 data for safusidenib in grade 2 IDH1-mutant glioma.
- Confirmed ORR 51.9%; 36-month PFS rate 79.1%; median follow-up 38.8 months; median PFS not reached.
